Posted by Michael Wonder on 14 Dec 2019
FDA approves Xeljanz XR (tofacitinib) extended-release tablets for the treatment of ulcerative colitis
12 December 2019 - Xeljanz XR provides adult patients living with moderately to severely active UC the first and only once-daily JAK inhibitor for managing their disease.
Pfizer announced today that the U.S. FDA has approved Xeljanz XR (tofacitinib) extended-release 11 mg and 22 mg tablets for the once-daily treatment of adult patients with moderately to severely active ulcerative colitis, after an inadequate response or intolerance to TNF blockers.
